Skip to main content
FDA OKs Akari's Coversin study for fatal pediatric disorder

The FDA has signed off on Akari Therapeutics' endpoints for its pivotal study to assess Coversin to treat pediatric patients with hematopoietic stem cell transplant-related thrombotic microangiopathy. The trial is scheduled to launch in the last quarter of 2019.

Full Story: